ArticleCancers2023

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.

Javier de la Rubia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.